Evidence map›Paper›PMID 38679679›Full record

ArticleAnnals of surgical oncology2024

Presacral Neuroendocrine Neoplasms: A Multi-site Review of Surgical Outcomes.

Tommaso Violante, Brenda Murphy, Davide Ferrari, Rondell P Graham, Patrick Navin, Amit Merchea, David W Larson, Eric J Dozois, Thorvardur R Halfdanarson, William R Perry

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tommaso ViolanteDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Brenda MurphyDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Davide FerrariDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Rondell P GrahamDepartment of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Patrick NavinDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Amit MercheaDivision of Colon and Rectal Surgery, Mayo Clinic, Jacksonville, FL, USA.
David W LarsonDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Eric J DozoisDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Thorvardur R HalfdanarsonDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
William R PerryDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA. Perry.William@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPresacral neuroendocrine neoplasms (PNENs) are rare tumors, with limited data on management and outcomes.

methodsA retrospective review of institutional medical records was conducted to identify all patients with PNENs between 2008 and 2022. Data collection included demographics, symptoms, imaging, surgical approaches, pathology, complications, and long-term outcomes.

resultsTwelve patients were identified; two-thirds were female, averaging 44.8 years of age, and, for the most part, presenting with back pain, constipation, and abdominal discomfort. Preoperative imaging included computed tomography scans and magnetic resonance images, with somatostatin receptor imaging and biopsies being common. Half of the patients had metastatic disease on presentation. Surgical approach varied, with anterior, posterior, and combined techniques used, often involving muscle transection and coccygectomy. Short-term complications affected one-quarter of patients. Pathologically, PNENs were mainly well-differentiated grade 2 tumors with positive synaptophysin and chromogranin A. Associated anomalies were common, with tail-gut cysts prevalent. Mean tumor diameter was 6.3 cm. Four patients received long-term adjuvant therapy. Disease progression necessitated additional interventions, including surgery and various chemotherapy regimens. Skeletal, liver, thyroid, lung, and pancreatic metastases occurred during follow-up, with no mortality reported. Kaplan-Meier analysis showed a 5-year local recurrence rate of 23.8%, disease progression rate of 14.3%, and de novo metastases rate of 30%.

conclusionThe study underscores the complex management of PNENs and emphasizes the need for multicenter research to better understand and manage these tumors. It provides valuable insights into surgical outcomes, recurrence rates, and overall survival, guiding future treatment strategies for PNEN patients.

Indexed as

Neuroendocrine TumorsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSacrumSurvival RateNeuroendocrinePresacral tumorRecurrenceSurgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.